U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17 SAEs worldwide (including two deaths) in ...

“We respect the ACIP recommendation and agree on the importance of continuing the stringent safety surveillance protocols that are in place,” said Juan Carlos Jaramillo, MD, Chief Medical Officer of ...